The FDA has had a busy month, overseeing the recall of nearly 88,000 implantable cardiac devices, juggling the continued rise of monkeypox cases in the United States and maintaining an active Breakthrough Devices program. This rundown covers some of the agency's biggest moves during that time. 

Three major pharmacy names will have to fork over hundreds of millions of dollars to two Ohio counties for their roles in the opioid epidemic, a judge has ruled.

The act is Biden’s third major piece of legislation to sign into law since the start of his term, and it accomplishes a healthcare task the Democrats have been wanting for years: enabling Medicare to negotiate prescription drug prices.

The new certification, based on recommendations published in Circulation, was developed to signal that a facility offers cardiac surgery and primary PCI at all times. 

Out of 305 U.S. employers surveyed, 35% said they now offer travel and lodging benefits for elective and medically necessary abortions.

The Centers for Disease Control and Prevention (CDC) has loosened COVID-19 guidelines, citing “significantly less risk of severe illness, hospitalization and death.”

The Federal Trade Commission (FTC) has cracked down on a health services provider accused of selling unqualified, sham health insurance plans through deceptive marketing and sales tactics. 

The American College of Cardiology has developed a helpful calculator that allows cardiologists and practice managers to estimate just how much the proposed 2023 MPFS could impact their practice.